{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=8&state=California",
    "query": {
      "state": "California",
      "city": "Fullerton",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 1115,
    "total_pages": 112,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=9&state=California&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=7&state=California&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T19:01:46.304Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06976203",
      "title": "A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "KarXT",
          "type": "DRUG"
        },
        {
          "name": "KarX-EC",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 586,
      "start_date": "2025-07-21",
      "completion_date": "2029-02-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-25T19:01:46.304Z",
      "location_count": 31,
      "location_summary": "Fullerton, California • Irvine, California • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06976203"
    },
    {
      "nct_id": "NCT00606684",
      "title": "A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "GW642444 6.25",
          "type": "DRUG"
        },
        {
          "name": "GW642444 3mcg",
          "type": "DRUG"
        },
        {
          "name": "GW642444 12.5mcg",
          "type": "DRUG"
        },
        {
          "name": "GW642444 25mcg",
          "type": "DRUG"
        },
        {
          "name": "GW642444 50mcg",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 602,
      "start_date": "2008-02",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2016-12-16",
      "last_synced_at": "2026-10-25T19:01:46.304Z",
      "location_count": 49,
      "location_summary": "Florence, Alabama • Jasper, Alabama • Montgomery, Alabama + 45 more",
      "locations": [
        {
          "city": "Florence",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00606684"
    },
    {
      "nct_id": "NCT02523014",
      "title": "Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Intracranial Meningioma",
        "Recurrent Meningioma",
        "NF2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Vismodegib",
          "type": "DRUG"
        },
        {
          "name": "FAK Inhibitor GSK2256098",
          "type": "DRUG"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2015-09-28",
      "completion_date": "2029-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-25T19:01:46.304Z",
      "location_count": 784,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 511 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02523014"
    },
    {
      "nct_id": "NCT00268216",
      "title": "Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Salmeterol 50mcg/ Fluticasone Propionate 500mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 6228,
      "start_date": "2000-09",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-10-25T19:01:46.304Z",
      "location_count": 190,
      "location_summary": "Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 152 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00268216"
    },
    {
      "nct_id": "NCT01243424",
      "title": "CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "linagliptin",
          "type": "DRUG"
        },
        {
          "name": "glimepiride",
          "type": "DRUG"
        },
        {
          "name": "linagliptin placebo",
          "type": "DRUG"
        },
        {
          "name": "glimepiride placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 6103,
      "start_date": "2010-11-11",
      "completion_date": "2018-08-21",
      "has_results": true,
      "last_update_posted_date": "2020-01-07",
      "last_synced_at": "2026-10-25T19:01:46.304Z",
      "location_count": 177,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 139 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01243424"
    },
    {
      "nct_id": "NCT05103358",
      "title": "Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tumor",
        "Tumor, Solid",
        "Metastasis",
        "Metastatic Cancer",
        "Cancer",
        "Cancer Metastatic",
        "Tumors",
        "Neoplasms",
        "Neoplasm Metastasis",
        "Solid Tumor",
        "Advanced Solid Tumor",
        "Advanced Cancer",
        "Malignant Solid Tumor",
        "Malignant Solid Neoplasm",
        "Malignant Neoplasm",
        "Malignant Tumor",
        "TSC",
        "TSC1",
        "TSC2",
        "Metastatic Solid Tumor",
        "Metastatic Neoplasm"
      ],
      "interventions": [
        {
          "name": "nab-sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aadi Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2022-03-10",
      "completion_date": "2024-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-25T19:01:46.304Z",
      "location_count": 159,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Prescott Valley",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05103358"
    },
    {
      "nct_id": "NCT05310071",
      "title": "A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Aducanumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 1027,
      "start_date": "2022-06-02",
      "completion_date": "2024-08-12",
      "has_results": true,
      "last_update_posted_date": "2025-04-23",
      "last_synced_at": "2026-10-25T19:01:46.304Z",
      "location_count": 130,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05310071"
    },
    {
      "nct_id": "NCT04126317",
      "title": "Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular (Wet) Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "aflibercept",
          "type": "DRUG"
        },
        {
          "name": "High-dose aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2019-11-04",
      "completion_date": "2021-11-30",
      "has_results": true,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-10-25T19:01:46.304Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Encino, California + 42 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04126317"
    },
    {
      "nct_id": "NCT03768414",
      "title": "Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stage III Distal Bile Duct Cancer AJCC v8",
        "Stage III Gallbladder Cancer AJCC v8",
        "Stage III Intrahepatic Cholangiocarcinoma AJCC v8",
        "Stage IIIA Distal Bile Duct Cancer AJCC v8",
        "Stage IIIA Gallbladder Cancer AJCC v8",
        "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8",
        "Stage IIIB Distal Bile Duct Cancer AJCC v8",
        "Stage IIIB Gallbladder Cancer AJCC v8",
        "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8",
        "Stage IV Distal Bile Duct Cancer AJCC v8",
        "Stage IV Gallbladder Cancer AJCC v8",
        "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8",
        "Stage IVA Gallbladder Cancer AJCC v8",
        "Stage IVB Gallbladder Cancer AJCC v8",
        "Unresectable Extrahepatic Bile Duct Carcinoma",
        "Unresectable Gallbladder Carcinoma",
        "Unresectable Intrahepatic Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 452,
      "start_date": "2019-02-07",
      "completion_date": "2024-10-28",
      "has_results": true,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-10-25T19:01:46.304Z",
      "location_count": 692,
      "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 448 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03768414"
    },
    {
      "nct_id": "NCT07201558",
      "title": "Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Surovatamig",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2025-12-02",
      "completion_date": "2028-06-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-25T19:01:46.304Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Fullerton, California • Plantation, Florida + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Allen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07201558"
    }
  ]
}